Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hyperglycemia01:29

Hyperglycemia

25
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose...
25
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Hypoglycemia01:26

Hypoglycemia

29
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
29
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

993
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of Switching from Prior Nonsteroidal Anti-inflammatory Drugs to Transdermal Diclofenac in Cancer Pain Management.

In vivo (Athens, Greece)·2026
Same author

Changes in CD8-positive lymphocytes following chemotherapy with concomitant bevacizumab in HER2-negative breast cancer.

Breast cancer (Tokyo, Japan)·2026
Same author

Therapeutic value of para-aortic lymph node dissection in gastric cancer with extensive lymph node metastasis: integrated analysis of three phase II trials (JCOG2212A).

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·2026
Same author

Increased treatment options and improved survival in real-world patients with HER2-positive advanced gastric cancer from 2011 to 2023.

Therapeutic advances in gastroenterology·2026
Same author

Usefulness of pharmacy outpatient clinic follow-up for maintaining relative dose intensity in patients on adjuvant CAPOX chemotherapy for gastric cancer.

Molecular and clinical oncology·2026
Same author

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab deruxtecan efficacy in patients with HER2-positive gastric cancer.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·2026
Same journal

Corrigendum.

Anticancer research·2026
Same journal

Geographic Variation in Stage at Diagnosis of Skin Cancer in the United States: A National Cancer Database Analysis.

Anticancer research·2026
Same journal

Anti-tumor Effects of Loureirin A Treatment in Colorectal Cancer Cells <i>via</i> Inhibition of AKT Phosphorylation.

Anticancer research·2026
Same journal

Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab <i>vs</i>. Sunitinib) for Advanced Renal Cell Carcinoma.

Anticancer research·2026
Same journal

Pulsed Electromagnetic Field Increases Doxorubicin-induced Mitotic Slippage in MDA-MB-231 Breast Cancer Cells.

Anticancer research·2026
Same journal

Geographic Disparities in Socioeconomic Factors and Advanced-stage Presentation in Rectosigmoid Cancer: A National Cancer Database Analysis.

Anticancer research·2026
See all related articles

Related Experiment Video

Updated: Apr 30, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.7K

Timing and Risk Factors for Hyperglycemia Associated With Anamorelin Administration.

Yoshihiro Amakawa1, Kazuo Kobayashi2, Yuma Nonomiya1,3

  • 1Department of Pharmacy, Japanese Foundation for Cancer Research, Cancer Institute Hospital, Tokyo, Japan.

Anticancer Research
|April 28, 2026
PubMed
Summary
This summary is machine-generated.

Anamorelin treatment for cancer cachexia can cause hyperglycemia, especially in patients with diabetes or high ALT levels. Most cases occur within the first month, necessitating close glucose monitoring.

Keywords:
Anamorelincancer cachexiadiabetes mellitushyperglycemialiver enzymesrisk factors

More Related Videos

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

97.6K
Homogeneous Time-resolved F&#246;rster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

8.3K

Related Experiment Videos

Last Updated: Apr 30, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.7K
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

97.6K
Homogeneous Time-resolved F&#246;rster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

8.3K

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Anamorelin, a ghrelin receptor agonist, treats cancer cachexia but may cause hyperglycemia.
  • Real-world data on anamorelin-induced hyperglycemia onset and risk factors are limited.

Purpose of the Study:

  • To determine the incidence, time to onset, and risk factors of hyperglycemia in patients receiving anamorelin.
  • To identify predictors for anamorelin-induced hyperglycemia in a real-world setting.

Main Methods:

  • Retrospective study of 129 cancer patients treated with anamorelin.
  • Hyperglycemia defined as blood glucose >200 mg/dl.
  • Logistic regression analysis to identify risk factors.

Main Results:

  • Hyperglycemia occurred in 29.5% of patients, with 20.2% experiencing Grade ≥3 events.
  • 81.6% of hyperglycemia cases developed within 28 days of treatment initiation.
  • Independent predictors included diabetes mellitus (OR=7.081) and elevated ALT >42 IU/l (OR=4.746).

Conclusions:

  • Anamorelin-induced hyperglycemia affects nearly one-third of patients, primarily within the first month.
  • Diabetes and elevated ALT are significant risk factors, indicating a need for vigilant glucose monitoring.